<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17888" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Aspart Insulin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rubin</surname>
            <given-names>Rochelle</given-names>
          </name>
          <aff>The Brooklyn Hospital Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Khanna</surname>
            <given-names>Niloufar R.</given-names>
          </name>
          <aff>California Northstate University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>McIver</surname>
            <given-names>Lindsey A.</given-names>
          </name>
          <aff>The Brooklyn Hospital Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rochelle Rubin declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Niloufar Khanna declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Lindsey McIver declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>6</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17888.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">This&#x000a0;activity discusses the indications, mechanism of action, administration, adverse effects, contraindications, monitoring, and toxicity of insulin aspart, a rapid-acting, human insulin analog FDA-approved for diabetes management. Insulin aspart can also be used to treat diabetic ketoacidosis, though this is an off-label use. This initiative facilitates informed decision-making and optimization of dosage regimens by&#x000a0;equipping healthcare professionals with comprehensive knowledge while minimizing adverse reactions. The interprofessional healthcare team's pivotal role in managing insulin aspart therapy is highlighted, and collaborative approaches for improving patient outcomes are emphasized.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the appropriate indications for insulin aspart.</p></list-item><list-item><p>Assess&#x000a0;the appropriate dosing of insulin aspart as part of a&#x000a0;diabetes regimen.</p></list-item><list-item><p>Evaluate the adverse event profile of insulin aspart.</p></list-item><list-item><p>Communicate&#x000a0;interprofessional team strategies for improving care coordination to advance appropriate clinical results with insulin aspart therapy as part of a diabetes glycemic control treatment plan.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17888&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17888">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17888.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Insulin aspart is a rapid-acting, human insulin analog that is FDA-approved&#x000a0;to improve glycemic control for treating type 1 and type 2 diabetes in adults and children.&#x000a0;Insulin aspart should be used in addition to a long-acting (basal) insulin for complete therapy unless already used in a continuous subcutaneous (insulin pump) or intravenous insulin infusion.<xref ref-type="bibr" rid="article-17888.r1">[1]</xref>&#x000a0;Rapid-acting insulin products aim to control post-meal blood glucose concentrations or reduce blood glucose in response to an elevated level, as in a correctional scale.<xref ref-type="bibr" rid="article-17888.r2">[2]</xref>&#x000a0;Insulin aspart is also available commercially with insulin degludec (long-acting insulin) or aspart protamine (intermediate-action insulin). Insulin degludec plus insulin aspart is&#x000a0;administered once or twice&#x000a0;daily with the&#x000a0;main meal. Insulin-naive patients should start insulin degludec/aspart at 0.2 to 0.4 units/kg/d. Insulin aspart/insulin aspart protamine is 30% insulin aspart, 70% insulin aspart protamine. Dosing for the protamine product starts at 0.5 units/kg/d. The daily dose is divided into&#x000a0;2 doses before meals, with 70% of the daily dose before breakfast and 30% of the daily dose before dinner.<xref ref-type="bibr" rid="article-17888.r3">[3]</xref>&#x000a0;The fast-acting&#x000a0;formulation of insulin aspart is also FDA-approved.<xref ref-type="bibr" rid="article-17888.r4">[4]</xref><xref ref-type="bibr" rid="article-17888.r5">[5]</xref><bold>&#x000a0;</bold>Faster-acting insulin aspart may help mitigate prandial excursions.<xref ref-type="bibr" rid="article-17888.r6">[6]</xref>&#x000a0;The&#x000a0;2023 Endocrine Society guidelines recommend using rapid-acting insulin analogs like insulin&#x000a0;aspart instead of regular human insulin for patients&#x000a0;on basal-bolus insulin therapy who are at high risk for hypoglycemia.<xref ref-type="bibr" rid="article-17888.r7">[7]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Insulin aspart may be used to treat diabetic ketoacidosis, though this is not an FDA-approved indication.<xref ref-type="bibr" rid="article-17888.r8">[8]</xref></p>
      </sec>
      <sec id="article-17888.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Insulin aspart regulates glucose metabolism by promoting storage and inhibiting the breakdown of glucose, fat, and amino acids. Insulin&#x000a0;reduces blood glucose levels by increasing peripheral glucose uptake, particularly in skeletal muscle and fat. Insulin enhances the storage of fat (lipogenesis) and protein synthesis. Insulin aspart also inhibits gluconeogenesis (hepatic glucose production), lipolysis (breakdown of lipids to fatty acids), and proteolysis (breakdown of proteins into amino acids). Maximum glucose-reducing effects occur within 1 to 3 hours and&#x000a0;last 3 to 5 hours. Insulin aspart is equipotent to regular insulin but has a faster onset and shorter duration of action. Thus, insulin aspart is preferred for mealtime insulin coverage as it can be administered every 4 hours.</p>
        <p>The pancreas naturally produces endogenous insulin. Insulin apart is manufactured through recombinant DNA&#x000a0;techniques using the&#x000a0;<italic toggle="yes">Saccharomyces cerevisiae </italic>expression system<italic toggle="yes">.</italic> Insulin aspart differs from endogenous insulin&#x000a0;as it&#x000a0;has an aspartic acid residue at position B28 instead of proline. Insulins can be categorized as rapid, short, intermediate, and long-acting depending on their pharmacologic effects (eg, onset, peak, and duration).<bold>&#x000a0;</bold>Rapid-acting insulin aspart&#x000a0;has a quicker onset of action than insulin aspart or short-acting (regular) insulin. The formulation of insulin aspart includes&#x000a0;2 excipients: niacinamide and L-arginine. Niacinamide&#x000a0;has a faster initial absorption following subcutaneous administration, while L-arginine is a stabilizing agent.<xref ref-type="bibr" rid="article-17888.r9">[9]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;Insulin aspart's onset of action occurs within 0.3 hours, with peak glucose-reducing effects occurring between 1 and 3 hours following subcutaneous injection. Rapid-acting insulin aspart may be dosed at 0.1, 0.2,&#x000a0;or 0.4 units/kg and&#x000a0;has an earlier onset of action, ranging from 16 to 20 minutes. Pharmacokinetic analysis demonstrated&#x000a0;an&#x000a0;onset of action difference of approximately 5&#x000a0;minutes between rapid-acting insulin aspart and aspart.<xref ref-type="bibr" rid="article-17888.r10">[10]</xref>&#x000a0;Factors influencing absorption&#x000a0;include injection site, physical activity, injection site blood flow, and body temperature.</p>
        <p><bold>Distribution:</bold>&#x000a0;Insulin aspart&#x000a0;binds weakly to plasma protein (&#x0003c;10%).</p>
        <p><bold>Metabolism:</bold>&#x000a0;Insulin aspart metabolism&#x000a0;occurs primarily in hepatic, renal, and adipose tissues.</p>
        <p><bold>Excretion:</bold>&#x000a0;Insulin aspart's clearance is approximately 1.2 L/h/kg. Its elimination half-life is approximately 81 minutes while faster-acting insulin aspart has a half-life of roughly 66 minutes.</p>
      </sec>
      <sec id="article-17888.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Insulin aspart is available as an injectable solution containing 100 units/mL and a prefilled syringe containing 100 units/mL.&#x000a0;Insulin aspart protamine and insulin aspart are available as an injectable suspension containing 100 units/mL (U-100), constituting 70% insulin aspart protamine and 30% aspart. This formulation is available in a 10 mL multiple-dose vial and a 3 mL prefilled pen.&#x000a0;Insulin aspart should be administered subcutaneously 5 to 10 minutes before a meal,&#x000a0;for 1 to 4 meals daily. To avoid lipodystrophy, injection sites should rotate between the top of the thighs, back of the upper arms, buttocks,&#x000a0;and abdomen. Injecting within 2 inches of the naval should be avoided. Insulin aspart may also be administered using a continuous subcutaneous infusion through an insulin pump or intravenously as a diluted solution. Intravenous administration requires close monitoring of blood glucose and serum potassium levels. Insulin aspart&#x000a0;can be mixed with NPH insulin but may only be administered&#x000a0;subcutaneously once mixed.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>
<bold>Type 1 Diabetes</bold>
</p>
        <p>Insulin aspart, or any rapid or short-acting insulin, is a mainstay of therapy for type 1 diabetes. According to&#x000a0;the&#x000a0;2023 American Diabetes Association guidelines, total daily insulin doses&#x000a0;range&#x000a0;from 0.4 to 1 units/kg/d, divided into long-acting and rapid-acting insulin, such as aspart. An initial breakdown of 50% basal insulin and 50% rapid-acting insulin is the&#x000a0;initial&#x000a0;therapy for most patients with type 1 diabetes and is adjusted based on blood glucose levels. Doses are patient-specific.</p>
        <p>
<bold>Type 2 Diabetes</bold>
</p>
        <p>Patients with type 2 diabetes are often prescribed&#x000a0;basal insulin rather than bolus insulin.<xref ref-type="bibr" rid="article-17888.r11">[11]</xref>&#x000a0;Insulin aspart may be added for further glycemic control in addition to oral medications or long-acting insulin. The recommended initial dose for&#x000a0;patients with type 2 diabetes&#x000a0;is 4 units per meal, 0.1 units/kg per meal, or 10% of the basal dose. If HgbA1c is less than 8%,&#x000a0;the basal insulin dose should be reduced when insulin is added&#x000a0;for meals.<xref ref-type="bibr" rid="article-17888.r12">[12]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold>&#x000a0;Patients with hepatic dysfunction are more likely to experience dysglycemia; it is recommended to use insulin aspart cautiously in these cases.</p>
        <p><bold>Renal impairment:</bold>&#x000a0;Changes in insulin aspart doses may be necessary&#x000a0;for individuals with renal or during acute illness to minimize the risk of hypoglycemia or hyperglycemia.</p>
        <p><bold>Pregnancy considerations:</bold>&#x000a0;Per the 2023 American Diabetes Association guidelines, insulin is recommended as the primary medication for managing hyperglycemia in gestational diabetes mellitus. Glyburide and metformin are not recommended as initial treatment options due to their potential to pass through the placenta to the fetus.&#x000a0;For patients using insulin pumps and basal-bolus therapy, it is recommended to test pre-meal insulin dosage and monitor post-meal to improve glycemic outcomes and reduce the risk of preeclampsia.<xref ref-type="bibr" rid="article-17888.r13">[13]</xref></p>
        <p><bold>Breastfeeding considerations:</bold>&#x000a0;Breastfeeding should be encouraged for all mothers, including those with diabetes, as it is nutritionally and immunologically beneficial for infants.&#x000a0;Breastfeeding may also provide long-term metabolic advantages for mother and child, including a reduced risk of type 2 diabetes in mothers with gestational diabetes. However, lactation can increase the risk of overnight hypoglycemia, necessitating insulin dosage adjustments. Exogenous insulin, including insulin analogs like aspart, is excreted into breast milk.&#x000a0;Insulin is a natural component of breast milk and&#x000a0;may&#x000a0;lower the risk of type 1 diabetes in breastfed infants.<xref ref-type="bibr" rid="article-17888.r14">[14]</xref>&#x000a0;According to the manufacturer label, breastfeeding benefits and the use of maternal insulin aspart require a thorough risk-benefit analysis, including potential adverse effects on the infant.</p>
        <p><bold>Pediatric patients:&#x000a0;</bold>Insulin aspart has received FDA approval&#x000a0;for patients with diabetes.&#x000a0;One study demonstrated that insulin pumps&#x000a0;in pediatric&#x000a0;patients that contain faster insulin aspart&#x000a0;result&#x000a0;in sustained improvements in glycemic control.<xref ref-type="bibr" rid="article-17888.r15">[15]</xref></p>
        <p><bold>Older patients:</bold> The practice of using sliding-scale insulin to address hyperglycemia in hospitalized patients, including older individuals, remains prevalent. However, relying solely on a&#x000a0;sliding-scale insulin regimen often fails to manage glucose fluctuations adequately. Multiple studies have demonstrated that a basal-bolus regimen&#x000a0;demonstrates&#x000a0;superior glycemic control and reduced rates of perioperative complications compared to sliding-scale insulin therapy.<xref ref-type="bibr" rid="article-17888.r16">[16]</xref></p>
      </sec>
      <sec id="article-17888.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The&#x000a0;most common adverse effect of insulin aspart is hypoglycemia, defined as a blood glucose level below 70 mg/dL. Signs and symptoms of hypoglycemia include dizziness, light-headedness, sweating, confusion, headache, blurred vision, slurred speech, tremors, tachycardia, irritability, or hunger.<xref ref-type="bibr" rid="article-17888.r17">[17]</xref> Severe cases of hypoglycemia (blood glucose level lower than 30 mg/dL) may lead to seizures or death. Hypoglycemia is dose-dependent and can be avoided&#x000a0;by reducing doses of insulin.<xref ref-type="bibr" rid="article-17888.r18">[18]</xref> After a hypoglycemic event, insulin dosages and glucose intake should be evaluated&#x000a0;and adjusted to prevent future hypoglycemic episodes.<xref ref-type="bibr" rid="article-17888.r19">[19]</xref>&#x000a0;Additional adverse reactions include allergic reactions (which may occur&#x000a0;locally at injection sites), lipodystrophy, rash, pruritus, and hypokalemia. Hypokalemia is dose-dependent, though the other additional adverse reactions are not.</p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Antidiabetic agents, ACE inhibitors,&#x000a0;fluoxetine, fibrates, monoamine oxidase inhibitors, salicylates, and octreotide can increase the risk of hypoglycemia. When using insulin aspart in conjunction with these medications, increasing the frequency of glucose monitoring is advised.</p>
          </list-item>
          <list-item>
            <p>Drugs that may&#x000a0;reduce the&#x000a0;blood glucose-lowering effect of insulin aspart include corticosteroids, diuretics, estrogens, niacin, oral contraceptives, protease inhibitors, thyroid hormone, albuterol, epinephrine, and atypical antipsychotics (eg, olanzapine, clozapine).<xref ref-type="bibr" rid="article-17888.r20">[20]</xref> Dose adjustment of insulin and more frequent glucose monitoring may be required.</p>
          </list-item>
          <list-item>
            <p>Pentamidine may increase or decrease the&#x000a0;blood glucose-reducing effect of insulin aspart. When insulin aspart is concomitantly administered with pentamidine, dose adjustments may be necessary.</p>
          </list-item>
          <list-item>
            <p>Beta-blockers and clonidine may&#x000a0;mask the signs and symptoms of hypoglycemia and should be used with caution.<xref ref-type="bibr" rid="article-17888.r21">[21]</xref><xref ref-type="bibr" rid="article-17888.r22">[22]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17888.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Insulin aspart is contraindicated&#x000a0;for patients with documented hypersensitivity to the drug or a component of the formulation.&#x000a0;Insulin aspart&#x000a0;is also contraindicated during episodes of hypoglycemia, though it may be resumed at lower doses once hypoglycemia resolves. Patients with hypersensitivity to other insulin products may try insulin aspart with appropriate&#x000a0;measures&#x000a0;available&#x000a0;in case of an adverse reaction (antihistamine and epinephrine as needed).</p>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Risk for pathogen transmission: </bold>Insulin aspart protamine and insulin aspart (Aspart 70/30) should not be shared between patients due to the risk of transmitting blood-borne pathogens, and patients using vials should not share needles or syringes.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Modifying regimen: </bold>Changes&#x000a0;to insulin therapy, including&#x000a0;changing&#x000a0;dose, manufacturer, injection site, or method of administration, can affect glycemic control and&#x000a0;increase the risk&#x000a0;of hypoglycemia or hyperglycemia. Modifications to an insulin regimen should only be made under medical supervision. Dosage adjustments of simultaneous anti-diabetic medications may be required.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Medication errors:</bold> Instances of unintentional interchanging of insulin products have been documented. Patients should verify the insulin label before each injection to reduce medication errors involving insulin aspart and other insulins.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Hypokalemia: </bold>Insulin aspart protamine/insulin aspart may&#x000a0;cause&#x000a0;hypokalemia by&#x000a0;shifting extracellular potassium into the cell. Untreated hypokalemia&#x000a0;can cause severe complications, such as ventricular arrhythmia.<xref ref-type="bibr" rid="article-17888.r23">[23]</xref><xref ref-type="bibr" rid="article-17888.r24">[24]</xref>&#x000a0;Potassium levels should be monitored when taking medications that affect the serum potassium concentration.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Fluid retention and heart failure:</bold> Concomitant use of thiazolidinediones, like pioglitazone (a PPAR-&#x003b3; agonist), may result in dose-dependent fluid retention, particularly when&#x000a0;co-administered with insulin aspart. This fluid retention can exacerbate heart failure and&#x000a0;requires vigilant monitoring&#x000a0;of patients receiving insulin aspart and PPAR-&#x003b3; agonists. If heart failure develops, discontinuation or dose reduction of the PPAR-&#x003b3; agonist should be considered.<xref ref-type="bibr" rid="article-17888.r25">[25]</xref><xref ref-type="bibr" rid="article-17888.r26">[26]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17888.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Critically ill patients receiving insulin aspart should have their blood glucose&#x000a0;level tested every 1 to 2 hours. Non-critically ill patients&#x000a0;on insulin aspart should routinely monitor their blood glucose concentration at home or in the hospital&#x000a0;to assess the efficacy of the insulin dose. This testing ideally occurs before or 2 hours after a meal.&#x000a0;Insulin dose adjustments should be based on testing results, typically&#x000a0;10% to 20% in either direction. All patients on insulin therapy should&#x000a0;have their HgbA1c tested every 6 months and electrolyte levels tested annually. Hemoglobin A1c should be monitored quarterly in patients who do not meet treatment goals or after changes in therapy. According to the American Diabetes Association, monitoring goals include a fasting blood glucose level of 80 to 130 mg/dL, a peak postprandial (1 to 2 hours&#x000a0;post-meal) blood glucose level of less than 180 mg/dL, and a HgbA1c level less than 7.0% for non-pregnant adult patients.&#x000a0;These goals may change for individual patients based on age, duration of diabetes, comorbid conditions, hypoglycemia unawareness, risk of a hypoglycemic event, and other considerations.&#x000a0;Patients with more comorbid conditions or a higher risk of harm&#x000a0;during a hypoglycemic event have less stringent goals. According to the Endocrine Society guidelines, patients with type 1 diabetes who receive multiple daily injections should receive continuous glucose monitoring instead of self-monitoring via fingerstick. Continuous glucose monitoring should be initiated in the inpatient setting for patients who are at high risk for hypoglycemia.<xref ref-type="bibr" rid="article-17888.r7">[7]</xref></p>
      </sec>
      <sec id="article-17888.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>An overdose of insulin aspart presents with hypoglycemia. In more severe cases, individuals may experience seizures, coma, or neurological impairment.&#x000a0;A systematic review on insulin overdose identified complications, including electrolyte disturbances (eg, hypokalemia, QTc prolongation, cardiac arrhythmia), prolonged cerebellar ataxia, and acute pulmonary edema.<xref ref-type="bibr" rid="article-17888.r27">[27]</xref></p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>Toxic effects of insulin aspart include hypoglycemia, which is treated by&#x000a0;administering glucose, dextrose, or oral carbohydrates to increase blood glucose levels. During a hypoglycemic episode, patients who can&#x000a0;eat&#x000a0;should consume 15 grams of carbohydrates (eg, glucose gel, tablets, or glucose-containing food).&#x000a0;Fifteen&#x000a0;minutes should pass&#x000a0;before rechecking blood glucose, and the treatment should be repeated if the patient is still hypoglycemic. Once the glucose level returns to normal, the patient should eat a meal within&#x000a0;an hour to prevent the recurrence of hypoglycemia.<xref ref-type="bibr" rid="article-17888.r28">[28]</xref> If the patient is unable or unwilling to consume oral glucose, intramuscular glucagon is used for ambulatory patients. Intravenous dextrose can be&#x000a0;administered&#x000a0;to conscious or unconscious patients with hypoglycemia; each dose contains 10 to 25 g. Blood glucose&#x000a0;levels should be&#x000a0;tested 15 minutes after receiving dextrose, and repeat doses of&#x000a0;intravenous dextrose or&#x000a0;intramuscular glucagon may be necessary until blood glucose returns to normal.&#x000a0;Additionally, insulin doses should be evaluated and adjusted after hypoglycemic events to prevent additional hypoglycemia.<xref ref-type="bibr" rid="article-17888.r29">[29]</xref>&#x000a0;Correction of electrolyte imbalances such as hypokalemia typically&#x000a0;requires potassium supplementation.</p>
      </sec>
      <sec id="article-17888.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>All healthcare professionals&#x000a0;administering insulin aspart should know its uses and&#x000a0;adverse effects. Insulin&#x000a0;aspart&#x000a0;is a rapid-acting, human insulin analog that is FDA-approved for treating type 1 and type 2 diabetes by improving glycemic control in adults and children. Insulin&#x000a0;aspart&#x000a0;may also be used off-label to treat diabetic ketoacidosis. Insulin&#x000a0;aspart&#x000a0;should be used in addition to a long-acting (basal) insulin for&#x000a0;comprehensive therapy unless used in a continuous subcutaneous (insulin pump) or intravenous insulin infusion. An endocrinologist should be consulted for optimal glycemic control. Pharmacists should verify the order and perform medication reconciliation. All interprofessional healthcare team members must educate the patient regarding proper dosing and usage of insulin aspart and any potential dosing adjustments to prevent hypoglycemia. Emergency medicine physicians should rapidly stabilize patients&#x000a0;with severe hypoglycemia. Patients with diabetic ketoacidosis&#x000a0;should be admitted&#x000a0;to the MICU under the&#x000a0;supervision of critical care physicians. Rapid-acting insulin products aim to control post-prandial blood glucose concentrations or reduce blood glucose to counter an elevated level, as in a correctional scale. Healthcare professionals must monitor glucose concentrations closely when administering insulin aspart&#x000a0;as it can induce hypoglycemia. Preparing some glucose-containing fluid or a meal is essential in case hypoglycemia develops.<xref ref-type="bibr" rid="article-17888.r30">[30]</xref>&#x000a0;An interprofessional team approach and open communication between clinicians (MDs, DOs, NPs, PAs), pharmacists, dieticians, nurses, and&#x000a0;endocrinologists&#x000a0;are necessary to&#x000a0;optimize patient outcomes on insulin aspart therapy.</p>
      </sec>
      <sec id="article-17888.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17888&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17888">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17888/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17888">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17888.s11">
        <title>References</title>
        <ref id="article-17888.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wen</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Hwang</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Hsiao</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Hung</surname>
                <given-names>WW</given-names>
              </name>
            </person-group>
            <article-title>Successful management of type IV hypersensitivity reactions to human insulin analogue with injecting mixtures of biphasic insulin aspart and dexamethasone.</article-title>
            <source>J Formos Med Assoc</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>118</volume>
            <issue>4</issue>
            <fpage>843</fpage>
            <page-range>843-848</page-range>
            <pub-id pub-id-type="pmid">30704815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17888.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>You</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Fulminant type 1 diabetes mellitus: Two case reports.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>98</volume>
            <issue>5</issue>
            <fpage>e14319</fpage>
            <pub-id pub-id-type="pmid">30702611</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17888.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Misra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mathieu</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Are newer insulin analogues better for people with Type 1 diabetes?</article-title>
            <source>Diabet Med</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>37</volume>
            <issue>4</issue>
            <fpage>522</fpage>
            <page-range>522-531</page-range>
            <pub-id pub-id-type="pmid">30585663</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17888.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dutta</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mohindra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mahajan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Performance of Fast-Acting Aspart Insulin as Compared to Aspart Insulin in Insulin Pump for Managing Type 1 Diabetes Mellitus: A Meta-Analysis.</article-title>
            <source>Diabetes Metab J</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>47</volume>
            <issue>1</issue>
            <fpage>72</fpage>
            <page-range>72-81</page-range>
            <pub-id pub-id-type="pmid">35746893</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17888.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haahr</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Heise</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>59</volume>
            <issue>2</issue>
            <fpage>155</fpage>
            <page-range>155-172</page-range>
            <pub-id pub-id-type="pmid">31667789</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17888.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>ElSayed</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Aleppo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Aroda</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Bannuru</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Bruemmer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Hilliard</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Isaacs</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Kahan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khunti</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Leon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lyons</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Prahalad</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pratley</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Seley</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Stanton</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Gabbay</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>on behalf of the American Diabetes Association</surname>
              </name>
            </person-group>
            <article-title>9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023.</article-title>
            <source>Diabetes Care</source>
            <year>2023</year>
            <month>Jan</month>
            <day>01</day>
            <volume>46</volume>
            <issue>Suppl 1</issue>
            <fpage>S140</fpage>
            <page-range>S140-S157</page-range>
            <pub-id pub-id-type="pmid">36507650</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17888.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCall</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Lieb</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Gianchandani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>MacMaster</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Maynard</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Murad</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Seaquist</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wolfsdorf</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Wiercioch</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Management of Individuals With Diabetes at High Risk for Hypoglycemia: An Endocrine Society Clinical Practice Guideline.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2023</year>
            <month>Feb</month>
            <day>15</day>
            <volume>108</volume>
            <issue>3</issue>
            <fpage>529</fpage>
            <page-range>529-562</page-range>
            <pub-id pub-id-type="pmid">36477488</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17888.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kildegaard</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Buckley</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Povlsen</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Seested</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ribel</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Olsen</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Ludvigsen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jeppesen</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Refsgaard</surname>
                <given-names>HHF</given-names>
              </name>
              <name>
                <surname>Bendtsen</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Kristensen</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Hostrup</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sturis</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Elucidating the Mechanism of Absorption of Fast-Acting Insulin Aspart: The Role of Niacinamide.</article-title>
            <source>Pharm Res</source>
            <year>2019</year>
            <month>Feb</month>
            <day>11</day>
            <volume>36</volume>
            <issue>3</issue>
            <fpage>49</fpage>
            <pub-id pub-id-type="pmid">30746556</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17888.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hsu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Buckingham</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Basina</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ekhlaspour</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>von Eyben</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lal</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Fast-Acting Insulin Aspart Use with the MiniMed<sup>TM</sup> 670G System.</article-title>
            <source>Diabetes Technol Ther</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-7</page-range>
            <pub-id pub-id-type="pmid">32520594</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17888.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heise</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pieber</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Danne</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Erichsen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Haahr</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2017</year>
            <month>May</month>
            <volume>56</volume>
            <issue>5</issue>
            <fpage>551</fpage>
            <page-range>551-559</page-range>
            <pub-id pub-id-type="pmid">28205039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17888.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siebel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Galderisi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Carria</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Tamborlane</surname>
                <given-names>WV</given-names>
              </name>
              <name>
                <surname>Sherr</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Reversal of Ketosis in Type 1 Diabetes Is Not Adversely Affected by SGLT2 Inhibitor Therapy.</article-title>
            <source>Diabetes Technol Ther</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>21</volume>
            <issue>3</issue>
            <fpage>101</fpage>
            <page-range>101-104</page-range>
            <pub-id pub-id-type="pmid">30688521</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17888.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Melo</surname>
                <given-names>KFS</given-names>
              </name>
              <name>
                <surname>Bahia</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Pasinato</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Porfirio</surname>
                <given-names>GJM</given-names>
              </name>
              <name>
                <surname>Martimbianco</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Riera</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Calliari</surname>
                <given-names>LEP</given-names>
              </name>
              <name>
                <surname>Minicucci</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Turatti</surname>
                <given-names>LAA</given-names>
              </name>
              <name>
                <surname>Pedrosa</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Schaan</surname>
                <given-names>BD</given-names>
              </name>
            </person-group>
            <article-title>Short-acting insulin analogues versus regular human insulin on postprandial glucose and hypoglycemia in type 1 diabetes mellitus: a systematic review and meta-analysis.</article-title>
            <source>Diabetol Metab Syndr</source>
            <year>2019</year>
            <volume>11</volume>
            <fpage>2</fpage>
            <pub-id pub-id-type="pmid">30622653</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17888.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>ElSayed</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Aleppo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Aroda</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Bannuru</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Bruemmer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Hilliard</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Isaacs</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Kahan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khunti</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Leon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lyons</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Prahalad</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pratley</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Jeffrie Seley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stanton</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Gabbay</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>on behalf of the American Diabetes Association</surname>
              </name>
            </person-group>
            <article-title>15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes-2023.</article-title>
            <source>Diabetes Care</source>
            <year>2023</year>
            <month>Jan</month>
            <day>01</day>
            <volume>46</volume>
            <issue>Suppl 1</issue>
            <fpage>S254</fpage>
            <page-range>S254-S266</page-range>
            <pub-id pub-id-type="pmid">36507645</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17888.r14">
          <label>14</label>
          <element-citation publication-type="book">
            <chapter-title>Insulin</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000050</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17888.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stamati</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sotiriou</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dimitriadou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Christoforidis</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of faster aspart in insulin pumps in children and adolescents with type 1 diabetes mellitus: A single-center study with real-world data.</article-title>
            <source>J Diabetes Complications</source>
            <year>2023</year>
            <month>Sep</month>
            <volume>37</volume>
            <issue>9</issue>
            <fpage>108587</fpage>
            <pub-id pub-id-type="pmid">37597378</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17888.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Umpierrez</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Pasquel</surname>
                <given-names>FJ</given-names>
              </name>
            </person-group>
            <article-title>Management of Inpatient Hyperglycemia and Diabetes in Older Adults.</article-title>
            <source>Diabetes Care</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>40</volume>
            <issue>4</issue>
            <fpage>509</fpage>
            <page-range>509-517</page-range>
            <pub-id pub-id-type="pmid">28325798</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17888.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fullerton</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Siebenhofer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jeitler</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Horvath</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Semlitsch</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Berghold</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gerlach</surname>
                <given-names>FM</given-names>
              </name>
            </person-group>
            <article-title>Short-acting insulin analogues versus regular human insulin for adult, non-pregnant persons with type 2 diabetes mellitus.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2018</year>
            <month>Dec</month>
            <day>17</day>
            <volume>12</volume>
            <issue>12</issue>
            <fpage>CD013228</fpage>
            <pub-id pub-id-type="pmid">30556900</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17888.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bai</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Comparison of a twice daily injection of insulin aspart 50 with insulin aspart 30 in patients with poorly controlled type 2 diabetes.</article-title>
            <source>Curr Med Res Opin</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>35</volume>
            <issue>6</issue>
            <fpage>1091</fpage>
            <page-range>1091-1096</page-range>
            <pub-id pub-id-type="pmid">30550344</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17888.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nunez Lopez</surname>
                <given-names>YO</given-names>
              </name>
              <name>
                <surname>Retnakaran</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zinman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pratley</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Seyhan</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Predicting and understanding the response to short-term intensive insulin therapy in people with early type 2 diabetes.</article-title>
            <source>Mol Metab</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>20</volume>
            <fpage>63</fpage>
            <page-range>63-78</page-range>
            <pub-id pub-id-type="pmid">30503831</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17888.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kolachalam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Longoni</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pintaudi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baldini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aringhieri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fasciani</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Annibale</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Maggio</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Scarselli</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Atypical Antipsychotics and Metabolic Syndrome: From Molecular Mechanisms to Clinical Differences.</article-title>
            <source>Pharmaceuticals (Basel)</source>
            <year>2021</year>
            <month>Mar</month>
            <day>08</day>
            <volume>14</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">33800403</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17888.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amna</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>&#x000d8;hlenschlaeger</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Saedder</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Sigaard</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Bergmann</surname>
                <given-names>TK</given-names>
              </name>
            </person-group>
            <article-title>Review of clinical pharmacokinetics and pharmacodynamics of clonidine as an adjunct to opioids in palliative care.</article-title>
            <source>Basic Clin Pharmacol Toxicol</source>
            <year>2024</year>
            <month>Apr</month>
            <volume>134</volume>
            <issue>4</issue>
            <fpage>485</fpage>
            <page-range>485-497</page-range>
            <pub-id pub-id-type="pmid">38275186</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17888.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mancia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kjeldsen</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Kreutz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pathak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grassi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Esler</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Individualized Beta-Blocker Treatment for High Blood Pressure Dictated by Medical Comorbidities: Indications Beyond the 2018 European Society of Cardiology/European Society of Hypertension Guidelines.</article-title>
            <source>Hypertension</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>79</volume>
            <issue>6</issue>
            <fpage>1153</fpage>
            <page-range>1153-1166</page-range>
            <pub-id pub-id-type="pmid">35378981</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17888.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thu Kyaw</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maung</surname>
                <given-names>ZM</given-names>
              </name>
            </person-group>
            <article-title>Hypokalemia-Induced Arrhythmia: A Case Series and Literature Review.</article-title>
            <source>Cureus</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>14</volume>
            <issue>3</issue>
            <fpage>e22940</fpage>
            <pub-id pub-id-type="pmid">35411269</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17888.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khiatah</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Frugoli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carlson</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>The Clinical Caveat for Treating Persistent Hypokalemia in Diabetic Ketoacidosis.</article-title>
            <source>Cureus</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>15</volume>
            <issue>7</issue>
            <fpage>e42272</fpage>
            <pub-id pub-id-type="pmid">37605707</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17888.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hong</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zhai</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development.</article-title>
            <source>Int J Mol Sci</source>
            <year>2018</year>
            <month>Jul</month>
            <day>27</day>
            <volume>19</volume>
            <issue>8</issue>
            <pub-id pub-id-type="pmid">30060458</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17888.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sheikh</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Hassan</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Adam</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Ogedegbe</surname>
                <given-names>OJ</given-names>
              </name>
              <name>
                <surname>Tabowei</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Barbarawi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yussuf</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Nor</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Association of Pioglitazone With Major Adverse Cardiovascular Events, All-Cause Mortality, and Heart Failure Hospitalizations: A Systematic Review.</article-title>
            <source>Cureus</source>
            <year>2023</year>
            <month>Oct</month>
            <volume>15</volume>
            <issue>10</issue>
            <fpage>e46911</fpage>
            <pub-id pub-id-type="pmid">37954768</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17888.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johansen</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Christensen</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>A Systematic Review on Insulin Overdose Cases: Clinical Course, Complications and Treatment Options.</article-title>
            <source>Basic Clin Pharmacol Toxicol</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>122</volume>
            <issue>6</issue>
            <fpage>650</fpage>
            <page-range>650-659</page-range>
            <pub-id pub-id-type="pmid">29316226</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17888.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dall</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Preclinical safety pharmacology studies on the rapid-acting insulin analogue insulin aspart.</article-title>
            <source>Arzneimittelforschung</source>
            <year>1999</year>
            <month>May</month>
            <volume>49</volume>
            <issue>5</issue>
            <fpage>463</fpage>
            <page-range>463-70</page-range>
            <pub-id pub-id-type="pmid">10367110</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17888.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gallagher</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Home</surname>
                <given-names>PD</given-names>
              </name>
            </person-group>
            <article-title>The effect of the optimal use of rapid-acting insulin analogues on insulin secretion in Type 2 diabetes.</article-title>
            <source>Diabetes Res Clin Pract</source>
            <year>2007</year>
            <month>Jun</month>
            <volume>76</volume>
            <issue>3</issue>
            <fpage>327</fpage>
            <page-range>327-34</page-range>
            <pub-id pub-id-type="pmid">17092597</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17888.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buse</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Carlson</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Komatsu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mosenzon</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Rose</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Buchholtz</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Horio</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kadowaki</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial.</article-title>
            <source>Diabetes Obes Metab</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>20</volume>
            <issue>12</issue>
            <fpage>2885</fpage>
            <page-range>2885-2893</page-range>
            <pub-id pub-id-type="pmid">30259644</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
